ARTICLE SUMMARY:
A surprisingly upbeat analyst perspective on the state of the molecular diagnostics industry cites greater clarity around LDT regulations and reimbursement as drivers of growth for infectious disease, specialty laboratories, and next-gen sequencing technologies.
Even as the diagnostics industry—across almost all sectors—has benefited from a plethora of scientific and technological advances in recent years, its struggles to reap the full rewards of those gains have dampened investor enthusiasm.
